129 related articles for article (PubMed ID: 25107643)
1. Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett's oesophagus.
Phelan JJ; MacCarthy F; Feighery R; O'Farrell NJ; Lynam-Lennon N; Doyle B; O'Toole D; Ravi N; Reynolds JV; O'Sullivan J
Cancer Lett; 2014 Nov; 354(1):122-31. PubMed ID: 25107643
[TBL] [Abstract][Full Text] [Related]
2. Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.
O'Farrell NJ; Feighery R; Picardo SL; Lynam-Lennon N; Biniecka M; McGarrigle SA; Phelan JJ; MacCarthy F; O'Toole D; Fox EJ; Ravi N; Reynolds JV; O'Sullivan J
BMC Cancer; 2016 Jul; 16():497. PubMed ID: 27431913
[TBL] [Abstract][Full Text] [Related]
3. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
4. The Mitochondrial Genes
Phelan JJ; MacCarthy F; O'Toole D; Ravi N; Reynolds JV; O'Sullivan J
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404157
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
6. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
7. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
8. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
9. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
[TBL] [Abstract][Full Text] [Related]
10. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
11. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
[TBL] [Abstract][Full Text] [Related]
12. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
14. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus.
Dvorak K; Payne CM; Chavarria M; Ramsey L; Dvorakova B; Bernstein H; Holubec H; Sampliner RE; Guy N; Condon A; Bernstein C; Green SB; Prasad A; Garewal HS
Gut; 2007 Jun; 56(6):763-71. PubMed ID: 17145738
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk in Barrett's oesophagus.
Dias Pereira A; Suspiro A; Chaves P
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.
Tselepis C; Perry I; Dawson C; Hardy R; Darnton SJ; McConkey C; Stuart RC; Wright N; Harrison R; Jankowski JA
Oncogene; 2002 Sep; 21(39):6071-81. PubMed ID: 12203119
[TBL] [Abstract][Full Text] [Related]
17. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
[TBL] [Abstract][Full Text] [Related]
18. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA
J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675
[TBL] [Abstract][Full Text] [Related]
19. Molecular biology of Barrett's cancer.
Atherfold PA; Jankowski JA
Best Pract Res Clin Gastroenterol; 2006; 20(5):813-27. PubMed ID: 16997163
[TBL] [Abstract][Full Text] [Related]
20. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
